Research ArticleBRIEF COMMUNICATION

Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval

Abuzar Moradi Tuchayi, Surekha Yadav, Fei Jiang, Sarasa T. Kim, Rachelle K. Saelee, Amanda Morley, Roxanna Juarez, Courtney Lawhn-Heath, Yingbing Wang, Ivan de Kouchkovsky and Thomas A. Hope
Journal of Nuclear Medicine May 2024, 65 (5) 735-739; DOI: https://doi.org/10.2967/jnumed.123.266842

Article Figures & Data

Figures

  • Figure
  • FIGURE 1.
    FIGURE 1.

    Waterfall plot, PSA change from baseline (%). UCSF = University of California San Francisco.

  • FIGURE 2.
    FIGURE 2.

    Kaplan–Meier survival curves for OS (A) and PSA PFS (B) in overall population. Restricted mean OS was 12.5 mo, and restricted mean PSA PFS was 5.8 mo.

  • FIGURE 3.
    FIGURE 3.

    (A) Restricted mean OS in patients who did not fulfill TheraP PSMA imaging criteria was 12.7 mo, vs. 12.4 mo in patients who met TheraP PSMA imaging criteria. (B) Restricted mean PSA PFS in patients who did not fulfill TheraP PSMA imaging criteria was 4.8 mo, vs. 6.0 mo in patients who met TheraP PSMA imaging criteria.

  • FIGURE 4.
    FIGURE 4.

    (A) Restricted mean OS in patients who met VISION laboratory criteria was 13.9 mo, vs. 9.7 mo in patients who did not. (B) Restricted mean PSA PFS in patients who met VISION laboratory criteria was 5.7 mo, vs. 6.0 mo in patients who did not. Patients with baseline laboratory issues had similar PSA response but decreased OS, compared with patients who did not have baseline laboratory issues.

Tables

  • TABLE 1.

    Patient Characteristics

    CharacteristicData
    Age (y)73 (range, 52–92)
    ECOG performance status 0 or 196 (96%)
    Site of disease
     Lung15 (15%)
     Liver22 (22%)
     Lymph node71 (71%)
     Bone95 (95%)
    PSA level (ng/mL)18.6 (range, 0.1–1,728.032)
    Gleason score at diagnosis
     8–1058 (58%)
     Unknown19 (19%)
    Previous prostatectomy31 (31%)
    Previous androgen-receptor-pathway inhibitor
     One regimen30 (30%)
     Two regimens66 (66%)
     More than 2 regimens3 (3%)
    Previous taxane therapy
     One regimen65 (65%)
     Two regimens34 (34%)
    PSMA SUVmax at baseline35.3 (interquartile range, 25.0–60.8)

    • ECOG = Eastern Cooperative Oncology Group.

    • Qualitative data are number and percentage; continuous data are median.

Additional Files

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords